This content is for general informational purposes only. It is not medical or legal advice and does not create a clinician-patient or attorney-client relationship. For guidance on your specific situation, consult a licensed clinician or attorney.

If you’re researching how to offer TB-500 at your business, HHS’s interim enforcement discretion policy now covers TB-500 acetate for 503A compounding when specific conditions are met. 

The policy sets limits on the substance, routes of administration, product composition, and pharmacy practices. Those conditions affect how a TB-500 program can operate, from pharmacy selection to patient care. 

Below, we’ll clarify some of the policy requirements, what TB-500 is and does, and five steps to walk through before adding it to your business.

What is TB-500 acetate?

What is TB-500?

A synthetic peptide that corresponds to a short fragment (amino acids 17–23) of thymosin beta-4, a 43-amino-acid protein the body produces naturally.

What the research shows

Most research on TB-500 and thymosin beta-4 comes from laboratory and animal studies. Human data are limited and do not establish safety or effectiveness.

In preclinical models, researchers have looked at possible roles in repairing heart tissue after a heart attack^1,2,3 and in healing injuries to the cornea^4,5,6 and the skin.^7,8 

Why businesses are wanting to add TB-500

Interest in peptides is growing, with Google Ads Keyword Planner data showing a 398% year-over-year increase in searches for “peptides” between June 2025 and July 2026 (Google Trends). For recovery, sports medicine, and wellness businesses, TB-500 is part of a broader market conversation about peptide-based services.

Is TB-500 legal to offer?

TB-500 is not FDA-approved. It is not included on the 503A Bulks List or classified in Category 1. HHS’s nonbinding interim enforcement discretion policy allows the agency to exercise enforcement discretion for certain conditions involving 503A compounding of TB-500 acetate. It does not approve the substance or establish that every TB-500 product or use is permitted.

The policy applies only when compounders meet its specific conditions. It does not override state pharmacy, prescribing, or professional practice requirements. HHS can also revise or withdraw the policy. 

The HHS interim policy’s conditions should inform pharmacy sourcing and program design from the start. For a more detailed review of the recent policy, see our recent blog covering it, here.

What forms of TB-500 does the policy cover?

The policy applies to a narrow formulation of TB-500. It covers:

• Substance: The Ac-LKKTETQ fragment only, not full-length thymosin beta-4.
• Salt form: Acetate only. Other salt forms are excluded.
• Routes of administration: Subcutaneous or intramuscular injection only. Oral, topical, and other routes are excluded.
• Product composition: One active pharmaceutical ingredient (API) per product. Products that combine TB-500 with another peptide, including BPC-157, are excluded.

The FDA has documented products marketed as blends of TB-500 and BPC-157 in its review of TB-500. Those combinations do not meet the policy’s single-API condition. 

If you’re considering a separate BPC-157 service, you can review our other blog on adding BPC-157 to a business.

How to offer TB-500 to your business

1. Decide where TB-500 acetate fits

Start with your existing services and patient population. Consider:

• Patient demand: Are patients already asking about peptide-based options?
• Clinical capacity: Do you have clinicians with the training and scope of practice to assess patients and manage treatment?
• Service fit: Does a TB-500 program make sense alongside your current wellness services?

TB-500 should fit a defined clinical service. If you’re planning to offer multiple peptide therapies, you’ll also need to consider how each fits your clinical services, prescribing workflows, pharmacy relationships, and patient care processes.

2. Choose a care delivery model

In-person vs. hybrid vs. virtual 

Decide whether the service will be in person, virtual, or hybrid. Your model affects how patients access consultations, prescriptions, administration, and follow-up.

It also determines certain regulatory restrictions. For instance, multi-state virtual care requires clinicians licensed in each state and alignment with that state’s compounding policies.

Ensure the delivery model works with your clinical team, pharmacy partner, and applicable state requirements. 

3. Build your clinical and regulatory foundation

Work with licensed prescribing clinicians to establish patient eligibility, clinical rationale, prescribing practices, and follow-up expectations. Each compounded prescription must be patient-specific and meet applicable interim enforcement policy and 503A requirements.

Determine how you will document clinical protocols, informed consent, adverse-event escalation, and the responsibilities of everyone involved in prescribing and care delivery. Review state rules for compounded prescribing, supervision, and administration before launching.

4. Vet your pharmacy partner

A 503A compounding pharmacy prepares medications for individual patients under valid prescriptions. These pharmacies operate under specific federal and state requirements, which are particularly important when sourcing a peptide such as TB-500. Additionally, the HHS’s interim enforcement policy lays out the requirements these pharmacies must meet to be eligible under the policy.

Ask the compounding pharmacy about:

• Licensure: Holds the required state license and operates as a 503A compounding pharmacy.
• TB-500 form: Compounds the specified Ac-LKKTETQ fragment, not full-length thymosin beta-4 or another salt form. 
• COA documentation: Obtains a valid certificate of analysis (COA) for each bulk substance, with testing for identity, purity, potency, and harmful contaminants.
• Supplier validation: Verifies the original manufacturer’s identity and documentation when the supply chain includes an intermediary, such as a repacker, relabeler, or reseller.
• Compounding standards: Follows applicable USP standards, including USP General Chapter 797.
• Product restrictions: Compounds TB-500 as the only active pharmaceutical ingredient (API) in each product. Combinations with BPC-157 or other peptides fall outside the policy and require individual prescriptions in separate vials. 
• Reporting and labeling: Follows the policy’s applicable requirements for reporting compounded products, adverse events, and product quality issues, as well as patient labeling. 

These are requirements set by the HHS’s draft interim enforcement policy. Review the pharmacy’s sourcing and documentation process before building the service around its products.

5. Standardize the care journey

Create a consistent process from the first inquiry through follow-up. Include patient intake and screening, clinician evaluation, informed consent, prescription coordination, administration or self-injection education, and follow-up.

Patients should understand that compounded TB-500 is not FDA-approved. Give them clear instructions for reporting side effects or injection-site concerns, and establish how your team will respond when an issue arises.

6. Set up the technology

Your systems should support intake, clinical documentation, patient messaging, pharmacy coordination, and follow-up. Make sure clinicians and support staff can see the information they need throughout the care journey.

7. Plan for policy changes

HHS’s interim policy is nonbinding and may change. Assign responsibility for monitoring federal and state requirements, and establish a process for reviewing your protocols, pharmacy relationship, patient communications, and service availability when guidance changes.

Work to add peptides to your business with OpenLoop®

Adding a peptide service takes more than finding a pharmacy. OpenLoop supports businesses with infrastructure for clinician-led care, including:

• 503A pharmacy partners where permitted by law
• Medically reviewed protocols
• A 50-state clinician network
• Compliance-aligned infrastructure
• 24/7/365 patient support

Contact Sales to discuss adding peptide services to your business.

Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality. The peptides discussed in this article have not been approved by FDA for recovery or performance. Compounded preparations require a prescription following an appropriate clinical evaluation, and no prescription is guaranteed. Availability varies based on clinical appropriateness, applicable federal and state laws, pharmacy availability, and other regulatory requirements. Not all peptide therapies are available in all states or through all pharmacies.

References:

1. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID 15565145. https://pubmed.ncbi.nlm.nih.gov/15565145/
2. Shrivastava S, Srivastava D, Olson EN, DiMaio JM, Bock-Marquette I. Thymosin β4 and cardiac repair. Ann N Y Acad Sci. 2010;1194:87-96.
3. Cardioprotection by Thymosin Beta 4 (review chapter). 2016. https://www.sciencedirect.com/science/chapter/bookseries/abs/pii/S0083672916300048 
4. Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007. PMID 19668473. https://pubmed.ncbi.nlm.nih.gov/19668473/
5. Sosne G, Chan CC, Thai K, et al. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo. Exp Eye Res. 2001;72:605-608.
6. Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74:293-299.
7. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335. https://pubmed.ncbi.nlm.nih.gov/10469335/
8. Philp D, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db [mice].